ETF Holdings Breakdown of MLTX

Stock Name	MoonLake Immunotherapeutics
Ticker	MLTX(USD) NASDAQ
TYPE	Common Stock
Country	USA

MLTX institutional holdings

The adjusted close for MLTX on 2025-11-12 was 12.77

The following institutional investment holdings of MLTX have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-12 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 17,117 USD 218,584 8.0% 12.77

2025-11-12 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 21,847 -0.3% USD 278,986 7.7% 12.77

2025-11-12 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 1,571 USD 20,062 8.0% 12.77

Total = 40,535 USD 517,632
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-12	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	17,117	USD 218,584 8.0%	12.77
2025-11-12	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	21,847 -0.3%	USD 278,986 7.7%	12.77
2025-11-12	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,571	USD 20,062 8.0%	12.77
Total =	40,535	USD 517,632

News associated with MLTX

Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $74.43: Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average […] - 2025-09-22 02:42:53
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of “Moderate Buy” from Brokerages: Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine research firms that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 […] - 2025-08-25 02:15:07
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to “Hold” at Redburn Atlantic: MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) was upgraded by research analysts at Redburn Atlantic to a “hold” rating in a report issued on Monday,Zacks.com reports. Several other analysts also recently commented on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $67.00 price objective on shares of MoonLake Immunotherapeutics in […] - 2025-07-30 02:20:44
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 2.7% – Still a Buy?: MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) shares traded up 2.7% during trading on Wednesday . The stock traded as high as $48.02 and last traded at $47.86. 425,225 shares were traded during mid-day trading, an increase of 11% from the average session volume of 384,204 shares. The stock had previously closed at $46.61. Wall […] - 2025-07-03 04:28:52
MoonLake Immunotherapeutics (NASDAQ:MLTX) Earns “Outperform” Rating from Royal Bank of Canada: MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $67.00 price objective on the stock. Royal Bank of Canada’s target price points to a potential upside of […] - 2025-06-05 02:29:04
Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 20,141 MoonLake Immunotherapeutics (NASDAQ:MLTX): Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 20,141 shares of the company’s stock, valued at approximately $1,091,000. Several other hedge funds also recently added to or reduced their stakes in the stock. Deutsche Bank AG […] - 2025-06-04 05:24:49
MoonLake Immunotherapeutics Breaks Above 200-Day Moving Average - Bullish for MLTX: In trading on Tuesday, shares of MoonLake Immunotherapeutics (Symbol: MLTX) crossed above their 200 day moving average of $45.66, changing hands as high as $49.48 per share. MoonLake Immunotherapeutics shares are currently trading up about 18.7% on the day. The chart below sho - 2025-06-03 14:16:02
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.: MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) by 13.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,456 shares of the company’s stock after purchasing an additional 1,866 shares during the period. […] - 2025-05-27 04:47:04
Nuveen Asset Management LLC Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX): Nuveen Asset Management LLC increased its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 595,581 shares of the company’s stock after purchasing an additional 14,792 shares during the quarter. Nuveen Asset Management LLC […] - 2025-05-22 05:58:59
Wolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Outperform: MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) was upgraded by analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a report released on Monday, MarketBeat Ratings reports. The firm presently has a $61.00 price target on the stock. Wolfe Research’s price objective would indicate a potential upside of 51.44% from […] - 2025-05-21 02:42:44
Ameriprise Financial Inc. Boosts Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX): Ameriprise Financial Inc. boosted its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) by 28.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 204,373 shares of the company’s stock after purchasing an additional 45,113 shares during the period. Ameriprise […] - 2025-05-19 04:30:54
Dimensional Fund Advisors LP Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX): Dimensional Fund Advisors LP acquired a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm acquired 64,384 shares of the company’s stock, valued at approximately $3,485,000. A number of other institutional investors and hedge funds have also made changes to their positions in MLTX. PNC Financial […] - 2025-05-14 04:32:47
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.50 Consensus Price Target from Analysts: MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has been assigned a consensus rating of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. […] - 2025-04-25 02:52:47
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sets New 12-Month Low – What’s Next?: MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) hit a new 52-week low during trading on Monday . The stock traded as low as $34.13 and last traded at $35.04, with a volume of 339603 shares. The stock had previously closed at $37.21. Analyst Ratings Changes MLTX has been the topic of a number of recent […] - 2025-04-08 04:50:55
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.50 Average PT from Analysts: MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has been assigned an average rating of “Buy” from the eight brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. […] - 2025-03-31 02:46:59
MoonLake Immunotherapeutics (NASDAQ:MLTX) Now Covered by Royal Bank of Canada: Royal Bank of Canada assumed coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research report released on Tuesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $67.00 price target on the stock. Several other analysts have also recently commented on the company. HC Wainwright reissued a “buy” rating and […] - 2025-03-19 05:12:49
Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $83.20: Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) have earned a consensus recommendation of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-03-06 04:45:40
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Cut by Handelsbanken Fonder AB: Handelsbanken Fonder AB reduced its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) by 14.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 11,100 shares of the company’s stock after selling 1,900 shares during the period. Handelsbanken Fonder AB’s holdings in MoonLake Immunotherapeutics were worth $601,000 at the end of the most […] - 2025-03-02 08:27:07

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.